Market Trends of Pleural Effusions Treatment Industry
This section covers the major market trends shaping the Pleural Effusions Treatment Market according to our research experts:
Transudative Pleural Effusions Segment Shows Lucrative Opportunity in the Pleural Effusions Treatment Market
Transudative pleural effusion (TPE) fluid is similar to the fluid that one normally has in his/her pleural space. It forms from liquid leaking across the normal pleura. This type rarely needs to be drained unless it is very large. Congestive heart failure (CHF) is the most common cause of all pleural effusions in developed countries and accounts for the overwhelming majority of transudative pleural effusions. Thus, owing to the increasing CHF the segment is anticipated to grow over the forecast period.
A transudative pleural effusion develops when the systemic factors influencing the formation or absorption of the pleural fluid are altered. The pleural surfaces are not involved in the primary pathologic process. The diagnosis of transudative effusion is simple to establish by examining the characteristics of the pleural fluid. As per the article 'Randomised trial of indwelling pleural catheters for refractory transudative pleural effusions' published in February 2022, refractory symptomatic transudative pleural effusions are an indication of pleural drainage. And there has been supportive observational evidence for the use of indwelling pleural catheters (IPCs) for transudative effusions. Such research related to TPE is anticipated to create demand for innovative treatment which is expected to fuel segment growth.
Moreover, the article 'Transudative and Exudative Pleural Effusion in Chronic Kidney Disease Patients: A Prospective Single-Center Study' published in October 2021 stated that the common causes of transudative pleural effusion are fluid overload, heart failure, and nephrotic syndrome, while the causes for exudative pleural effusion are pneumonia, tuberculosis (TB), pulmonary embolisms, or diseases causing pleuro-renal syndromes, like systemic lupus erythematosus. As the burden of such diseases is increasing, the risk of TPE also increasing, which is creating demand for treatments available for TPE, thereby fuelling segment growth.
Therefore, owing to the factors mentioned above, the segment is anticipated to witness growth over the analysis period.
North America Dominates the Studied Market Over the Forecast Period
North America is anticipated to witness growth over the forecast period and dominate the market. Among other countries in the region, the United States is leading the market, due to factors such as an increase in healthcare expenditure, increasing research and developments, and a rising prevalence of heart diseases. Additionally, the rising geriatric population across the United States is the primary driver for the pleural effusions market.
For people with cancer and heart failure, pleural effusions are often malignant. The increasing burden of diseases in the United States is expected to create opportunities for the pleural effusions market. The data updated by the American Cancer Society's Cancer Statistics 2022, nearly 1.9 million new cancer cases are estimated to be diagnosed in the United States in the year 2022.
In addition, heart failure is a growing health and economic burden for the United States because of the aging population. As per the American Heart Association data updated in April 2022, nearly 115 million people have hypertension, 100 million have obesity, 92 million have prediabetes, 26 million have diabetes, and 125 million have atherosclerotic cardiovascular diseases (CVD) in the United States, which are known to be the risk factors for the development of heart failure. Thus, the high burden of cardiovascular diseases creates the risk of pleural effusions among the target population in the United States. This is expected to fuel market growth.
Therefore, owing to the increasing prevalence of pleural effusions, the market studied is anticipated to witness growth in the region.
